CN108078941A - aripiprazole oral disintegrating tablet and preparation method thereof - Google Patents
aripiprazole oral disintegrating tablet and preparation method thereof Download PDFInfo
- Publication number
- CN108078941A CN108078941A CN201810121237.3A CN201810121237A CN108078941A CN 108078941 A CN108078941 A CN 108078941A CN 201810121237 A CN201810121237 A CN 201810121237A CN 108078941 A CN108078941 A CN 108078941A
- Authority
- CN
- China
- Prior art keywords
- aripiprazole
- disintegrating tablet
- oral disintegrating
- disintegrant
- aripiprazole oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Abstract
The invention belongs to technical field of medicine, are specifically related to a kind of Aripiprazole oral disintegrating tablet and preparation method thereof.Aripiprazole oral disintegrating tablet is prepared using torching mark as raw material using Aripiprazole, disintegrant, interior plus filler, additional filler, corrigent and lubricant；In terms of mass fraction, raw material composition is as follows：Aripiprazole 1 30%, disintegrant 0.2 5%, interior plus filler 30 65%, additional filler 30 65%, corrigent 2 20% and lubricant 0.5 3%.Aripiprazole oral disintegrating tablet disintegration rate prepared by the present invention reaches 10 seconds or so, influence factor stability and the related substance of acceleration sample are almost unchanged, and hardness finds no reduction situation, the tasty no sand feeling of sweet mouthfeel, stability is good, and hardness does not influence disintegration and production efficiency is high.
Description
Technical field
The invention belongs to technical field of medicine, are specifically related to a kind of Aripiprazole oral disintegrating tablet and preparation method thereof.
Background technology
Aripiprazole is a kind of qualone derivative, belongs to third generation atypical antipsychotic, by great Zhong drugmakers
It develops, for treating various acute and chronic schizophrenia and schizoaffective disorder, listing dosage form has aripipazole piece, A Li
Piperazine azoles oral disintegrating tablet, Aripiprazole particle, Aripiprazole long-acting injection.The advantage of oral disintegrating tablet be it is convenient to take, it is rapid-action etc..
At present, Aripiprazole oral disintegrating tablet preparation process is essentially tabletting after freeze drying technology, dry granulation, powder is directly pressed
Piece, the rapid disintegration of oral disintegrating tablet requirement, in order to reach this purpose, solution is that collapsing for higher amount is added in preparation process at present
Agent is solved, and the tablet suppressed has smaller hardness.So there are the problem of be if auxiliary material moisture control it is bad, in stability mistake
Tablets do swell occurs for Cheng Zhonghui；The tablet of the smaller hardness of compacting can cause to occur Tab attrition during subsequent packages even broken
Piece.
Patent CN106913548A uses dry granulation tabletting, and the Aripiprazole oral disintegrating tablet of preparation is in the larger situation of hardness
Under, it influences to be disintegrated, more than 3kg disintegration times are long, and more than 4kg disintegration times go beyond the limit 1min, and 3kg is once with the time
Extend, hardness tapers into, and stability is bad.
The content of the invention
The purpose of the present invention is overcome the deficiencies in the prior art, using the disintegrant of less dosage, obtain larger hardness
Sample disintegration is also very rapid in the case that sample, even hardness reach 12KG, and the stability that product is placed is good, and product is without sand
Grain sense is good in taste.
Aripiprazole oral disintegrating tablet of the present invention with Aripiprazole, disintegrant, interior plus filler, additional filler, is rectified
Taste agent and lubricant prepare Aripiprazole oral disintegrating tablet for raw material using torching mark；In terms of mass fraction, raw material forms such as
Under：
Wherein：
Interior plus filler is the one or more in lactose, mannitol, xylitol or sorbierite；In terms of mass fraction, use
Amount accounts for the 30-65%, most preferably preferably 30-50%, 45-50% of raw material gross mass.
Additional filler is fumaric acid odium stearate, lactose, mannitol or lactose compoundIn one kind
It is or a variety of.
Corrigent is tartaric acid, citric acid, aspartame, Sucralose, Steviosin, citric acid, acesulfame potassium or vanillic aldehyde
In one or more.
Disintegrant is one kind or more in crospovidone, croscarmellose sodium, sodium carboxymethyl starch or L-HPC
Kind；It is preferred that the one or more in crospovidone, croscarmellose sodium or sodium carboxymethyl starch；Most preferably crosslinking is poly-
Tie up one or both of ketone or sodium carboxymethyl starch；In terms of mass fraction, dosage accounts for the 0.2-5% of raw material total amount, preferably
0.5-0.4%, most preferably 1-3%.
Lubricant is one kind in magnesium stearate or sodium stearyl fumarate, preferably sodium stearyl fumarate.
The preparation method of Aripiprazole oral disintegrating tablet of the present invention, specifically includes following steps：
(1) Aripiprazole with interior plus filler is mixed, adds in disintegrant and corrigent continues to mix, incorporation time 5-60
Minute；
(2) mixed material in step (1) is added in hot-melt extruded granulator and carries out hot-melt extruded, hot-melt extruded object
It is pelletized with granulator, granulation sieve mesh number is 20-40 mesh；
(3) add in additional filler to be mixed, add disintegrant and lubricant, incorporation time 5-60 minutes；
(4) material in step (3) is transferred in tablet press machine and carries out tabletting；
(5) tablet suppressed is subjected to plastic-aluminum, double aluminium or bottled packaging.
Wherein：
The mass ratio of the disintegrant of addition and the disintegrant of addition in step (3) is 1 in step (1):8-2:1, preferably 1:
5-1:1, most preferably 1:3-1:2.
Melting temperature during hot-melt extruded described in step (2) is 140-180 DEG C.
The preparation process of the present invention is hot-melt extrusion process, by Aripiprazole and lactose, mannitol, xylitol, sorbierite
One or more, part corrigent, partial disintegration agent mixed with mixer, carries out hot-melt extruded after mixing, heat
Molten extrusion temperature, which is set, to be needed to be adjusted temperature according to different auxiliary material or different auxiliary material ratio, to ensure that material can reach melting
State, extrudate are pelletized with 20-40 mesh screens, are added in lubricant, partial disintegration agent, lactose or lactose compound and are pressed
The tablet suppressed is carried out plastic-aluminum, double aluminium or bottled packaging by piece.
As a preferred technical solution, the preparation method of Aripiprazole oral disintegrating tablet of the present invention specifically includes
Following steps：
(1) Aripiprazole mix with interior plus filler, interior plus filler select a kind of disintegrant and one or more its
His auxiliary material, melting temperature and the bulk pharmaceutical chemicals of one or more of which auxiliary material approach.The preferred mannitol of meltbility auxiliary material, xylitol,
Lactose or sorbierite etc., interior plus the preferred tartaric acid of corrigent, DL- tartaric acid or citric acid.
Mixing apparatus preferred three-dimensional mixer, wherein mixer come from Central-South medicine machine.Mix 5-20 revs/min of rotating speed, mixing
Time 5-60 minute surveys uniformity of dosage units after the completion of mixing, carries out next step operation after mixing, such as finds that mixing is uneven,
Continue to mix.
(2) uniformly mixed material is added in hot-melt extruded granulator hopper and carries out hot-melt extruded, wherein hot melt squeezes
Go out the ME-3 type hot-melt extruded granulators that equipment is selected from the production of Shenzhen Xinyi spy Science and Technology Ltd., melting temperature is in 140-
180 DEG C, actual temp needs to be adjusted according to interior plus filler species.Hot-melt extruded object with oscillating granulator (yk-60) into
Row granulation, granulation sieve mesh number are 20-40 mesh.
(3) add in additional filler to be mixed, additional filler need to contain at least one disintegrant and lubricant.In order to
Ensure better compressibility and mouthfeel, the preferable auxiliary material of one or more compressibility and corrigent need to be added in, in order to ensure mouth
Sense is preferably added to the auxiliary materials such as lactose or mannitol and one or more corrigents without feeling of grittiness.
Mixing apparatus preferred three-dimensional mixer, wherein mixer come from Central-South medicine machine.Mix 5-20 revs/min of rotating speed, mixing
Time 5-60 minute surveys uniformity of dosage units after the completion of mixing, carries out next step operation after mixing, such as finds that mixing is uneven,
Continue to mix.
(4) uniformly mixed material is transferred in tablet press machine hopper, carries out tabletting, tablet press machine selection Shanghai day and pharmacy
The ZP-10 type tablet press machines of machinery plant adjust tableting pressure and loading.Different size tablet controls different hardness：
5 milligrams and preferred 80-120 milligrams of the piece weight of 10 milligrams of specifications, preferred 3-8 kilograms of tablet hardness；
Preferred 120-180 milligrams of the piece weight of 15 milligrams of specifications, preferred 5-10 kilograms of tablet hardness；
Preferred 250-350 milligrams of the piece weight of 30 milligrams of specifications, preferred 7-12 kilograms of tablet hardness.
(5) tablet suppressed is subjected to aluminum-plastic packaged, mounted box or vanning.
(6) detect, be put in storage.
Tablet hardness test is using the extremely big intelligent tablet hardness instrument YD-35 of day hair in Tianjin.
The invention has the advantages that：
Aripiprazole oral disintegrating tablet disintegration rate prepared by the present invention can reach 10 seconds or so；Influence factor stability and
The related substance of acceleration sample is almost unchanged, and hardness finds no reduction situation；The tasty no sand feeling of sweet mouthfeel, production efficiency
Height, stability is good, does not influence disintegration rate under larger hardness.
Specific embodiment
The invention will be further described with reference to embodiments.
Embodiment 1
Aripiprazole oral disintegrating tablet (specification 5mg, batch 10000)
The preparation method of Aripiprazole oral disintegrating tablet is as follows：
(1) Aripiprazole, xylitol, mannitol and tartaric acid are mixed.
(2) material that will be uniformly mixed carries out hot-melt extruded, and hot melting temperature control is at 140 DEG C, and the block of extrusion is with 30
Mesh screen is pelletized.
(3) crospovidone, Sucralose, lactose compound are added inIt is carried out with fumaric acid odium stearate
Mixing.
(4) tabletting, theoretical piece weight 96.5mg, 5 kilograms of hardness are carried out after mixing.
(5) tablet carries out aluminum-plastic packaged, mounted box, vanning.
(6) examine, be put in storage.
The Aripiprazole oral disintegrating tablet prepared to embodiment 1 is detected, and the results are shown in Table 1：
1 embodiment of table, 1 Aripiprazole oral disintegrating tablet the performance test results
(Otsuka Pharmaceutical Europe Ltd) manufacturer is big tomb pharmacy (Europe).
Embodiment 2
Aripiprazole oral disintegrating tablet (specification：5mg)
The preparation method of Aripiprazole oral disintegrating tablet is as follows：
(1) Aripiprazole, xylitol, mannitol, tartaric acid, crospovidone are mixed.
(2) material that will be uniformly mixed carries out hot-melt extruded, and hot melting temperature control is at 138 DEG C, and the block of extrusion is with 30
Mesh screen is pelletized.
(3) crospovidone, Sucralose, lactose compound are added inFumaric acid odium stearate is mixed
It closes.
(4) tabletting, theoretical piece weight 92.5mg, 5 kilograms or so of hardness are carried out after mixing.
(5) tablet carries out aluminum-plastic packaged, mounted box, vanning.
(6) examine, be put in storage.
The Aripiprazole oral disintegrating tablet prepared to embodiment 2 is detected, and the results are shown in Table 2：
The Aripiprazole oral disintegrating tablet the performance test results of 2 embodiment 2 of table
Embodiment 3
Aripiprazole oral disintegrating tablet (specification：10mg, batch 10000)
The preparation method of Aripiprazole oral disintegrating tablet is as follows：
(1) Aripiprazole, lactose, mannitol, citric acid, sodium carboxymethyl starch are mixed.
(2) material that will be uniformly mixed carries out hot-melt extruded, and hot melting temperature control is at 145 DEG C, and the block of extrusion is with 30
Mesh screen is pelletized.
(3) sodium carboxymethyl starch, aspartame, lactose compound are added inFumaric acid odium stearate carries out
Mixing.
(4) tabletting, theoretical piece weight 97.5mg, 5 kilograms or so of hardness are carried out after mixing.
(5) tablet carries out aluminum-plastic packaged, mounted box, vanning.
(6) examine, be put in storage.
The Aripiprazole oral disintegrating tablet prepared to embodiment 3 is detected, and the results are shown in Table 3：
The Aripiprazole oral disintegrating tablet the performance test results of 3 embodiment 3 of table
Embodiment 4
Aripiprazole oral disintegrating tablet (specification：15mg, batch 10000)
The preparation method of Aripiprazole oral disintegrating tablet is as follows：
(1) Aripiprazole, xylitol, mannitol, tartaric acid, crospovidone are mixed.
(2) material that will be uniformly mixed carries out hot-melt extruded, and hot melting temperature control is at 140 DEG C, and the block of extrusion is with 30
Mesh screen is pelletized.
(3) crospovidone, acesulfame potassium, vanillic aldehyde, lactose, fumaric acid odium stearate is added in be mixed.
(4) tabletting, theoretical piece weight 137mg, 8 kilograms or so of hardness are carried out after mixing.
(5) tablet carries out aluminum-plastic packaged, mounted box, vanning.
(6) examine, be put in storage.
The Aripiprazole oral disintegrating tablet prepared to embodiment 4 is detected, and the results are shown in Table 4：
The Aripiprazole oral disintegrating tablet the performance test results of 4 embodiment 4 of table
Embodiment 5
Aripiprazole oral disintegrating tablet (specification：10mg, batch 10000)
The preparation method of Aripiprazole oral disintegrating tablet is as follows：
(1) Aripiprazole, xylitol, mannitol, tartaric acid, sodium carboxymethyl starch are mixed.
(2) material that will be uniformly mixed carries out hot-melt extruded, and hot melting temperature control is at 140 DEG C, and the block of extrusion is with 30
Mesh screen is pelletized.
(3) crospovidone, Sucralose, lactose compound are added inFumaric acid odium stearate is mixed
It closes.
(4) tabletting, theoretical piece weight 96.5mg, 7 kilograms or so of hardness are carried out after mixing.
(5) tablet carries out aluminum-plastic packaged, mounted box, vanning.
(6) examine, be put in storage.
The Aripiprazole oral disintegrating tablet prepared to embodiment 5 is detected, and the results are shown in Table 5：
The Aripiprazole oral disintegrating tablet the performance test results of 5 embodiment 5 of table
Embodiment 6
Aripiprazole oral disintegrating tablet (specification：30mg, batch：10000)
The preparation method of Aripiprazole oral disintegrating tablet is as follows：
(1) Aripiprazole, xylitol, mannitol, tartaric acid, sodium carboxymethyl starch are mixed.
(2) material that will be uniformly mixed carries out hot-melt extruded, and hot melting temperature control is at 145 DEG C, and the block of extrusion is with 30
Mesh screen is pelletized.
(3) crospovidone, Sucralose, lactose compound are added inFumaric acid odium stearate is mixed
It closes.
(4) tabletting, theoretical piece weight 292.5mg, 11 kilograms or so of hardness are carried out after mixing.
(5) tablet carries out aluminum-plastic packaged, mounted box, vanning.
(6) examine, be put in storage.
The Aripiprazole oral disintegrating tablet prepared to embodiment 6 is detected, and the results are shown in Table 6：
The Aripiprazole oral disintegrating tablet the performance test results of 6 embodiment 6 of table
By taking specification is the Aripiprazole oral disintegrating tablet of 15mg as an example, influence of the hardness to disintegration time is investigated, the results are shown in Table 7：
7 hardness of table influences comparison sheet to disintegration time
Own product dissolution as can be seen from the data increases with hardness, no significant change.And by other listing product prescriptions and work
The sample that skill is made substantially increases with the increase of hardness.Its reason may be due to by hot-melt extruded particle it is comparatively dense
After adding in additional disintegrant tabletting, particle deformation is smaller, and tablet is easier to disintegration into particle after disintegrant water suction disintegration.It is and common
Method of granulating, more compressible under larger pressure, granulated becomes bigger, more close between particle and particle, in media as well
The speed that moisture enters the piece heart is obstructed, and disintegration is slack-off.
Claims (9)
1. a kind of Aripiprazole oral disintegrating tablet, it is characterised in that：With Aripiprazole, disintegrant, interior plus filler, additional filler,
Corrigent and lubricant prepare Aripiprazole oral disintegrating tablet for raw material using torching mark；In terms of mass fraction, raw material composition
It is as follows：
2. Aripiprazole oral disintegrating tablet according to claim 1, it is characterised in that：Interior plus filler is lactose, mannitol, wood
One or more in sugar alcohol or sorbierite.
3. Aripiprazole oral disintegrating tablet according to claim 1, it is characterised in that：Additional filler is fumaric acid stearic acid
Sodium, lactose, mannitol or lactose compoundOne or more in 8.
4. Aripiprazole oral disintegrating tablet according to claim 1, it is characterised in that：Corrigent is tartaric acid, citric acid, A Si
One or more in Pa Tan, Sucralose, Steviosin, citric acid, acesulfame potassium or vanillic aldehyde.
5. Aripiprazole oral disintegrating tablet according to claim 1, it is characterised in that：Disintegrant is crospovidone, crosslinking carboxylic
One or more in sodium carboxymethylcellulose pyce, sodium carboxymethyl starch or L-HPC.
6. Aripiprazole oral disintegrating tablet according to claim 1, it is characterised in that：Lubricant is that magnesium stearate or stearic acid are rich
One kind in horse acid sodium.
7. a kind of preparation method of Aripiprazole oral disintegrating tablet described in claim 1, it is characterised in that：Specifically include following step
Suddenly：
(1) Aripiprazole with interior plus filler is mixed, adds in disintegrant and corrigent continues to mix, 5-60 points of incorporation time
Clock；
(2) mixed material in step (1) is added in hot-melt extruded granulator and carries out hot-melt extruded, hot-melt extruded object system
Grain machine is pelletized, and granulation sieve mesh number is 20-40 mesh；
(3) add in additional filler to be mixed, add disintegrant and lubricant, incorporation time 5-60 minutes；
(4) material in step (3) is transferred in tablet press machine and carries out tabletting；
(5) tablet suppressed is subjected to plastic-aluminum, double aluminium or bottled packaging.
8. the preparation method of Aripiprazole oral disintegrating tablet according to claim 7, it is characterised in that：Addition in step (1)
The mass ratio of disintegrant and the disintegrant of addition in step (3) is 1:8-2:1.
9. the preparation method of Aripiprazole oral disintegrating tablet according to claim 7, it is characterised in that：Described in step (2)
Melting temperature during hot-melt extruded is 140-180 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810121237.3A CN108078941A (en) | 2018-02-07 | 2018-02-07 | aripiprazole oral disintegrating tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810121237.3A CN108078941A (en) | 2018-02-07 | 2018-02-07 | aripiprazole oral disintegrating tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108078941A true CN108078941A (en) | 2018-05-29 |
Family
ID=62193955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810121237.3A Pending CN108078941A (en) | 2018-02-07 | 2018-02-07 | aripiprazole oral disintegrating tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108078941A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2082735A1 (en) * | 2008-01-23 | 2009-07-29 | Helm AG | Amorphous Aripiprazole and Process for the Preparation thereof |
| CN102670533A (en) * | 2012-05-17 | 2012-09-19 | 浙江华海药业股份有限公司 | Stable aripiprazole orally-disintegrating tablets and preparation method thereof |
| CN103284968A (en) * | 2010-04-13 | 2013-09-11 | 齐鲁制药有限公司 | Aripiprazole composition microcrystalline orally disintegrating tablets and preparation method thereof |
| CN106580868A (en) * | 2017-01-24 | 2017-04-26 | 广州帝奇医药技术有限公司 | Implant and preparation method thereof |
-
2018
- 2018-02-07 CN CN201810121237.3A patent/CN108078941A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2082735A1 (en) * | 2008-01-23 | 2009-07-29 | Helm AG | Amorphous Aripiprazole and Process for the Preparation thereof |
| CN103284968A (en) * | 2010-04-13 | 2013-09-11 | 齐鲁制药有限公司 | Aripiprazole composition microcrystalline orally disintegrating tablets and preparation method thereof |
| CN102670533A (en) * | 2012-05-17 | 2012-09-19 | 浙江华海药业股份有限公司 | Stable aripiprazole orally-disintegrating tablets and preparation method thereof |
| CN106580868A (en) * | 2017-01-24 | 2017-04-26 | 广州帝奇医药技术有限公司 | Implant and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0933079B1 (en) | Free-flowable, directly compressible starch as binder, disintegrant and filler for compression tablets and hard gelatine capsules | |
| CN107875136B (en) | Amoxicillin medicinal preparation and preparation method thereof | |
| ZA200209283B (en) | Continuous production of pharmaceutical granulation. | |
| CN103083318A (en) | Bilayer tablet comprising telmisartan and amlodipine | |
| CN102048734A (en) | Pharmaceutical composition | |
| CN101166533A (en) | Micronized tanaproget and compostions containing same | |
| CN105213346B (en) | A kind of pharmaceutical composition and preparation method thereof containing cinacalcet hydrochloride | |
| CN104042580B (en) | A kind of valsartan dispersible tablet and preparation method thereof | |
| CN105147614B (en) | A kind of solid pharmaceutical preparation and preparation method thereof including BIBW 2992MA2 | |
| CN102526748B (en) | Oral tablet containing Valsartan, Hydrochioro and Amlodipine Besylate Tablet | |
| CN104661653B (en) | The method of production sustained release potassium citrate wax-matrix tablet | |
| CN103356498B (en) | Mosapride citrate sustained-release tablet | |
| CN104586803B (en) | A kind of preparation method of the net microcrystalline cellulose compositions of En Gelie | |
| WO2016104643A1 (en) | Solid preparation for treating diabetes | |
| CN108078941A (en) | aripiprazole oral disintegrating tablet and preparation method thereof | |
| CN106727368A (en) | A kind of Dapagliflozin pharmaceutical composition and preparation method thereof | |
| CN106667939A (en) | Orally disintegrating tablet containing vilazodone hydrochloride and preparation method thereof | |
| JP4774739B2 (en) | Kampo extract-containing tablet composition and method for producing the same | |
| JP2007523140A (en) | Compressed coated tablets and their manufacture | |
| CN112451499B (en) | Sunitinib malate preparation and preparation method thereof | |
| CN108014343A (en) | A kind of pharmaceutical composition for treating breast cancer and preparation method thereof | |
| CN110051639B (en) | Rapidly disintegrating nicergoline tablet and preparation method thereof | |
| CN114533693B (en) | Paracetamol effervescent tablet for children and preparation process thereof | |
| CN115089550B (en) | Preparation method of mosapride citrate particles | |
| JP2004517111A (en) | Pharmaceutical formulations containing citalopram |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180529 |
|
| RJ01 | Rejection of invention patent application after publication |